- Home
- OSCR vs ZLAB Comparison
OSCR vs ZLAB Comparison
Compare OSCR & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OSCR
- ZLAB
- Stock Information
- Founded
- OSCR 2012
- ZLAB 2013
- Country
- OSCR United States
- ZLAB China
- Employees
- OSCR N/A
- ZLAB N/A
- Industry
- OSCR Accident &Health Insurance
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- OSCR Finance
- ZLAB Health Care
- Exchange
- OSCR Nasdaq
- ZLAB Nasdaq
- Market Cap
- OSCR 3.3B
- ZLAB 3.0B
- IPO Year
- OSCR 2021
- ZLAB 2017
- Fundamental
- Price
- OSCR $15.91
- ZLAB $26.05
- Analyst Decision
- OSCR Hold
- ZLAB Strong Buy
- Analyst Count
- OSCR 8
- ZLAB 3
- Target Price
- OSCR $21.56
- ZLAB $55.00
- AVG Volume (30 Days)
- OSCR 3.3M
- ZLAB 482.4K
- Earning Date
- OSCR 02-04-2025
- ZLAB 02-25-2025
- Dividend Yield
- OSCR N/A
- ZLAB N/A
- EPS Growth
- OSCR N/A
- ZLAB N/A
- EPS
- OSCR 0.12
- ZLAB N/A
- Revenue
- OSCR $8,215,224,000.00
- ZLAB $355,748,000.00
- Revenue This Year
- OSCR N/A
- ZLAB $49.04
- Revenue Next Year
- OSCR $23.92
- ZLAB $46.70
- P/E Ratio
- OSCR $129.13
- ZLAB N/A
- Revenue Growth
- OSCR 51.10
- ZLAB 35.01
- 52 Week Low
- OSCR $10.66
- ZLAB $13.48
- 52 Week High
- OSCR $23.79
- ZLAB $36.60
- Technical
- Relative Strength Index (RSI)
- OSCR 57.90
- ZLAB 50.14
- Support Level
- OSCR $13.89
- ZLAB $23.82
- Resistance Level
- OSCR $15.53
- ZLAB $25.64
- Average True Range (ATR)
- OSCR 0.87
- ZLAB 1.24
- MACD
- OSCR 0.26
- ZLAB 0.06
- Stochastic Oscillator
- OSCR 93.34
- ZLAB 64.45
About OSCR Oscar Health Inc.
Oscar Health Inc is a health insurance company. The company provides various insurance plans for individuals, families, and employees. Also, the company provides virtual care, doctor support, scheduling appointments, and other related services. The company provides plans in the Medicare Advantage program to adults who are age 65 and older and eligible for traditional Medicare but who instead select coverage through a private market plan.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.